Mr. Meltz joined PaxVax in 2014 and is currently its Executive Vice President and Chief Business Development and Legal Officer. He reports to the company’s Chief Executive Officer and works closely with its Board of Directors and senior management team. Mr. Meltz manages PaxVax’s Business Development, Legal, Compliance and Government Affairs, and Public Policy functions and previously oversaw its finance department. Prior to joining PaxVax, Mr. Meltz worked at Biogen Idec (now known as Biogen), where he initially was the lead U.S. Commercial lawyer for Tysabri, an injectable MS drug with a black box warning, and the lead U.S. Commercial lawyer supporting the launch of Tecfidera, an oral MS blockbuster drug, and subsequently was the lead lawyer for the Global Medical Affairs group. Earlier in his career, Mr. Meltz worked at Novartis as Head of Legal for the Vaccines business unit’s North America and Latin America groups and counseled each group’s senior management team. He was also the lead lawyer for the U.S. launch of Menveo, a meningococcal vaccine. Before joining the industry, Mr. Meltz practiced law at the international law firm Bingham McCutchen LLP (now part of Morgan Lewis & Bockius LLP), where he concentrated his practice on mergers and acquisitions, venture capital financing, securities regulation and general corporate matters. Mr. Meltz received his Juris Doctor from Boston College Law School and his Bachelor of Arts with Departmental Honors in Psychology from Yale University where he played varsity football. Mr. Meltz is licensed to practice law in the Commonwealth of Massachusetts. Mr. Meltz joined PaxVax in 2014 and is currently its Executive Vice President and Chief Business Development and Legal Officer. He reports to the company’s Chief Executive Officer and works closely with its Board of Directors and senior management team. Mr. Meltz manages PaxVax’s Business Development, Legal, Compliance and Government Affairs, and Public Policy functions and previously oversaw its finance department. Prior to joining PaxVax, Mr. Meltz worked at Biogen Idec (now known as Biogen), where he initially was the lead U.S. Commercial lawyer for Tysabri, an injectable MS drug with a black box warning, and the lead U.S. Commercial lawyer supporting the launch of Tecfidera, an oral MS blockbuster drug, and subsequently was the lead lawyer for the Global Medical Affairs group. Earlier in his career, Mr. Meltz worked at Novartis as Head of Legal for the Vaccines business unit’s North America and Latin America groups and counseled each group’s senior management team. He was also the lead lawyer for the U.S. launch of Menveo, a meningococcal vaccine. Before joining the industry, Mr. Meltz practiced law at the international law firm Bingham McCutchen LLP (now part of Morgan Lewis & Bockius LLP), where he concentrated his practice on mergers and acquisitions, venture capital financing, securities regulation and general corporate matters. Mr. Meltz received his Juris Doctor from Boston College Law School and his Bachelor of Arts with Departmental Honors in Psychology from Yale University where he played varsity football. Mr. Meltz is licensed to practice law in the Commonwealth of Massachusetts.

Management